Qube Research & Technologies LTD Autolus Therapeutics PLC Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Qube Research & Technologies LTD holds 802,081 shares of AUTL stock, worth $3.09 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
802,081
Previous 48,575
1551.22%
Holding current value
$3.09 Million
Previous $309,000
803.24%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding AUTL
# of Institutions
114Shares Held
167MCall Options Held
34.2KPut Options Held
19.5K-
Syncona Portfolio LTD Guernsey, Channel Islands, X021.3MShares$82.2 Million86.45% of portfolio
-
Blackstone Inc New York, NY20.5MShares$78.9 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA17.9MShares$68.9 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$58.8 Million1.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$47.5 Million0.59% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $350M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...